洛克斯抑制破坏了原-整体-MYC轴,以抑制侵袭性叶膜癌的进展
Renée L Flaherty1, Flavia Hughes1, George Sflomos2
1Institute of Cancer Research London United Kingdom.
Cancer research
|February 18, 2026
概括
一种新型药物PXS-5505有效地重塑了侵袭性叶膜癌 (ILC) 中富含原蛋白的基质,阻止了瘤生长和转移. 这种泛lysyl氧化酶抑制剂对治疗这种研究不足的乳腺癌亚型有前途.
科学领域:
- 在瘤学瘤学.
- 癌症生物学 癌症生物学
- 生物化学 生物化学
背景情况:
- 侵袭性叶状癌 (ILC) 占乳腺癌的15%,但由于在试验中的代表性不足和临床前模型有限,缺乏向治疗.
- 在ILC中CDH1损失会对富含原的细胞外基质 (ECM) 产生依赖.
研究的目的:
- 在临床前ILC模型中评估泛lysyl氧化酶抑制剂PXS-5505的疗效.
- 调查PXS-5505影响瘤微环境的机制,并确定潜在的反应生物标志物.
主要方法:
- 为ILC建立导管内异种移植模型.
- 用PXS-5505治疗和瘤扩张和转移性播种的评估.
- 全基因组的CRISPR屏幕用于识别CDH1.1的合成致命伙伴.
- 对ECM重塑,基因表达 (MYC,NF-κB,AP-1) 和整体蛋白表达 (ITGAV,ITGB5) 的分析.
主要成果:
- 在ER+和三阴性ILC模型中,PXS-5505重塑了纤维状原蛋白,阻止了瘤扩张和转移性播种.
- 在PXS-5505治疗时没有观察到系统性毒性.
- 克里斯普尔屏幕确定ITGAV和ITGB5是CDH1.1的合成致命合作伙伴.
- 在LOX抑制下调ITGAV,ITGB5,MYC,NF-κB和AP-1.
- 原纤维密度/对齐和MYC/AP-1基因特征作为药理动力学读数.
结论:
- 在ILC中发现了一个可处理的ECM-integrin-MYC轴.
- PXS-5505显示出作为ILC治疗剂的潜力,需要进一步调查.
- PXS-5505可能适用于机会窗口试验,单独或与内分泌疗法结合使用.
相关概念视频
Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
The Intrinsic Apoptotic Pathway
8.8K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
8.8K
mTOR Signaling and Cancer Progression
4.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.9K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K


